Assembly Biosciences, Inc. announced data from its herpes simplex virus (HSV) program featured in three poster presentations at the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), held in Vienna, Austria, on April 11-15, 2025.
“We are encouraged by the data shared from our clinical and preclinical studies of ABI-5366, supporting its potential to be a once-weekly or once-monthly oral treatment option for those with recurrent genital herpes, an underserved disease space,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “Importantly, our analysis of genital herpes prevalence and treatment patterns further underscores the substantial burden of genital herpes in the United States and wide variability in antiviral treatment patterns. This guides our efforts to improve therapeutic options in a field that has seen little innovation for decades.”
Read the full company press release here.
Source : Assembly Biosciences, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.